FP187: DMF in Multiple Sclerosis

Jefferies Healthcare Conference

June 3, 2015
Forward-Looking Statements

This presentation contains forward-looking statements about Forward Pharma A/S based on management’s current expectations which are subject to known and unknown uncertainties and risks. Our actual results could differ materially from those discussed due to a number of factors, including, but not limited to, our ability to raise additional financing on favorable terms, the success of our clinical trials, our ability to obtain regulatory approval of FP187, our success in maintaining and defending our patent estate and other risk factors included in our filings with the U.S. Securities and Exchange Commission. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.
FWP – The Investment Opportunity

FP187 Clinical Development

Intellectual Property

Capital Structure

Multiple Opportunities Ahead
Introduction to Forward Pharma

- Focused on DMF since 2004

- FP187: Proprietary slow release formulation of DMF

- 480 mg daily dose in MS patent application allowable and '871 patent interference declared

- MS NDA-enabling Phase 3 trial: 1 trial, 1 year endpoint

- IPO priced 10/14/2014, raised $235 M in gross proceeds

- Well capitalized to pursue patent and development strategies
FP187 Clinical Differentiation

- Same active pharmaceutical ingredient as Tecfidera® but new formulation may improve tolerability
- FP187 utilizes an “erosion matrix”

Formulation Differentiation

FP187
- Enteric-coated slow release formulation

Tecfidera®
- Enteric-coated immediate release formulation

DMF
* 480 mg/day is the only approved dose for RR-MS

Source: Biogen Idec
6 separate patent applications with claims to 480 mg/day with the same priority date of October 7, 2005

<table>
<thead>
<tr>
<th>Application Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>US</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 11/576,871         | Treating MS with DMF at 480 mg/day  
* Interference declared; FWP as Senior Party – 4/13/15 |
| 14/213,399         | Up-titration of DMF to 480 mg/day doses for the treatment of MS |
| 14/212,503         | Treating MS with DMF at 480 mg/day to reach certain MMF levels in the bloodstream |
| **European**       |             |
| EP14172398.1       | Treating MS with 480 mg/day of DMF wherein the pH controlled release compositions have an enteric coat  
* Issued – 5/20/15 |
| EP14172396.5       | Treating MS with 480 mg/day of controlled release DMF |
| EP14172390.8       | Treating MS with 480 mg/day of controlled release DMF with particular in vitro dissolution profile |
FP187 core composition patents filed at least 1 year, 4 months, 1 day earlier

- **WO '342 / US '871**
  - **10/07/05:** WO'342 Filed (application designating US)
  - **04/13/06:** WO'342 Published
  - Exp. 2025

- **FP187**
  - **10/08/04:** 1st Danish Filing Date

- **Tecfidera®**
  - **02/08/07:** '514, '537 Filed
  - Exp. 2028

- **End of Phase II FDA meeting**

2004 - 2008

---

2015 © Forward Pharma A/S
USPTO Interference Proceeding

- **Interference declared April 13, 2015**
  A patent interference is an administrative proceeding at the USPTO used to determine which party is the first to invent a common invention claimed by both parties

- **Forward has “Senior Party” status**
  The Senior Party has the earliest effective filing date to the common invention; entitled to the presumption that it is the first inventor

- **Interference ongoing**
  Average length is 13 months to resolution, excluding appeals
Interference Process

Motions Phase (~1 yr)
Three-judge panel at PTAB decides any patentability and senior party issues

Priority Phase (~1 yr)
Three-judge panel gives final judgment on priority

Resolution
Average Time to Resolution: 13 months, excluding appeals
Senior vs. Junior Party

**Forward Pharma: “Senior Party”**
Has the earliest effective filing date to the invention; entitled presumption that it invented first

**Biogen: “Junior Party”**
Has the burden of proof to show a date of invention that predates our invention

USPTO asked that at the initial conference call, “Biogen should be prepared to discuss how it expects to prevail in the interference.”
A method of treating multiple sclerosis comprising orally administering (a) a therapeutically effective amount of dimethyl fumarate...wherein the therapeutically effective amount...is \textbf{480 mg per day}

- \textbf{Latest filing date: 10/07/05}

A method of treating multiple sclerosis comprising orally administering...a therapeutically effective amount of dimethyl fumarate...about \textbf{480 mg per day}

- \textbf{Earliest filing date: 02/08/07}
Schedule for the Interference

- May 22, 2015: Each party files and serves a list of motions the party intends to file
- May 29, 2015: Initial conference call to discuss the interference
- July 10, 2015: File authorized motions and file priority statements
- July 31, 2015: File authorized responsive motions
- September 11, 2015: File oppositions to all motions
- October 23, 2015: File all replies
- November 23, 2015: File request for oral argument, motions to exclude and observations
- December 21, 2015: File oppositions to motions to exclude evidence and file response to observations
- January 9, 2016: File replies to oppositions to motions to exclude
- January 16, 2016: File exhibits and sets of motions
- January 22, 2016: Default oral argument
Potential royalty initiation date

- Forward’s '871 claims published on April 10, 2014
- Biogen was provided a copy of Forward’s published claims on September 8, 2014
Reasonable Royalty

- Patentee who wins infringement case is entitled to no less than a “reasonable royalty”

- Legal framework:
  - Hypothetical negotiation between willing licensor and willing licensee on the eve of infringement
    - What is the maximum the infringer would pay the patentee to be able to stay on the market
    - What is the minimum the patentee would accept to allow accused product to stay on the market

- Analysis assumes: patent is valid and infringed
## Royalty Regimes

<table>
<thead>
<tr>
<th></th>
<th>Academic Inventor</th>
<th>Industrial Inventor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Competitive Product</td>
<td>NO</td>
<td>YES</td>
</tr>
<tr>
<td>Active R&amp;D Spend</td>
<td>NO</td>
<td>YES</td>
</tr>
<tr>
<td>Ability to Commercialize</td>
<td>NO</td>
<td>YES</td>
</tr>
<tr>
<td>Opportunity Cost</td>
<td>LOW</td>
<td>HIGH</td>
</tr>
<tr>
<td>Royalty</td>
<td>LOW</td>
<td>HIGH</td>
</tr>
<tr>
<td>Example</td>
<td>Cabilly</td>
<td>Late-stage Biotech Deals</td>
</tr>
</tbody>
</table>
Potential FP187 Patent Protection in the US

- **CORE COMPOSITION**: "480 MG" 2025
- **EROSION MATRIX (US ’420)**: 2030
- **US ’514**: "480 MG" 2028

2015 © Forward Pharma A/S
Potential FP187 Patent Protection in Europe

10 years regulatory exclusivity

EP '063 EROSION MATRIX 2030

“480 MG” CORE COMPOSITION 2025

FP187

Tecfidera®

EP '537 “480 MG” 2028

+1 year if approved in second indication with clinical benefit over existing therapies


2015 © Forward Pharma A/S
USPTO and EPO Claims Covering 480 mg/day

6 separate patent applications with claims to 480 mg/day with the same priority date of October 7, 2005

<table>
<thead>
<tr>
<th>Application Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>US</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 11/576,871         | Treating MS with DMF at 480 mg/day  
* Interference declared; FWP as Senior Party – 4/13/15 |
| 14/213,399         | Up-titration of DMF to 480 mg/day doses for the treatment of MS |
| 14/212,503         | Treating MS with DMF at 480 mg/day to reach certain MMF levels in the bloodstream |
| **European**       |             |
| EP14172398.1       | Treating MS with 480 mg/day of DMF wherein the pH controlled release compositions have an enteric coat  
* Issued – 5/20/15 |
| EP14172396.5       | Treating MS with 480 mg/day of controlled release DMF |
| EP14172390.8       | Treating MS with 480 mg/day of controlled release DMF with particular in vitro dissolution profile |
Other Intellectual Property

- EP2316430 ('430) Patent
  - Granted with oral hearing June 24 – 25th, 2015 at EPO

- Erosion Matrix Patent Family
  - US and EU patents covering FP187
Forward Pharma filed a lawsuit against BIIB on November 18, 2014

Alleges infringement by Biogen's marketing of Tecfidera® in Germany with a label instructing a daily dose of 480 mg for MS

An oral proceeding is scheduled for February 16, 2016 at the Regional Court in Dusseldorf
Support for our IP

- **US:** USPTO has twice found allowable 480 mg/day to treat MS as an invention; PTAB declared interference with Forward Pharma as Senior Party

- **Europe:** '8.1 EU patent application issued

- **Competitors:** References to our 480 mg/day patent application as prior art in opposition proceedings against Biogen Idec in Europe
BIIB to FWP Current Relative Valuation

$99 B
Tecfidera® Cumulative Projection**

$94 B
BIIB Market Cap*

480 mg DMF

$1.5 B
FWP Market Cap

* As of 5/29/15
**Leerink estimates 2013 – 2028
Clinical Trials to Date

**FP187-101, 102, 103**
- 3 Phase 1 clinical trials of 62 healthy male volunteers
- Studied:
  - PK properties of MMF
  - Comparative bioavailability vs. Fumaderm®
  - Safety and tolerability

**Results**
- Few and low peaks of MMF
- Similar bioavailability – Profile indicating controlled and sustained release

**FP187-201**
- Phase 2 clinical trial of 252 psoriasis patients
- Studied:
  - Efficacy using PASI75 as the primary endpoint
  - Safety and tolerability

**Results**
- PASI75 in 500 mg group (PP) (45.5%) vs. placebo (13.5%) – p<0.01
- Low flushing rates (17% for 500 mg and 13% for 750 mg FP187 arms)
- 100% of flushing events were mild or moderate

318 patients treated to date with FP187
**Planned Phase 3 Trial in RR-MS (FDA Meeting August 2013): FP187-MS-301**

**Trial Design**

- Double-blind, double-dummy 48 week active comparator with two FP187 dosage groups

- One Phase 3 trial, 48 weeks in alignment with FDA pre-IND meeting in August 2013

- IND for MS filed on April 30, 2014; FDA “may proceed” letter sent on June 10, 2014

**Primary Endpoint:** Reduction of ARR at Week 48 vs. IFNβ

**Key Secondary Endpoint:** Progression of EDSS / SAD
Well capitalized following IPO with an efficient business model

**Balance Sheet ($)**

<table>
<thead>
<tr>
<th>Cash and Cash Equivalents</th>
<th>3/31/15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$206.4 M</td>
</tr>
</tbody>
</table>

**Income Statement ($ in thousands)**

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended March 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D Expenses</td>
<td>$4,320</td>
</tr>
<tr>
<td>G&amp;A Expenses</td>
<td>4,069</td>
</tr>
<tr>
<td>Operating Loss</td>
<td>$8,389</td>
</tr>
</tbody>
</table>
Corporate Overview

Management

- **Peder M. Andersen, MD**  
  Chief Executive Officer & Chief Operating Officer  
  - More than 25 years experience in the pharmaceutical industry  
  - Several years experience in business development experience, both generic and proprietary in Europe

- **Joel Sendek**  
  Chief Financial Officer  
  - 18 years as a sell-side analyst, most recently as Managing Director, Healthcare Equity Research, Stifel Financial Corp.  
  - Former Head of Business Development, Progenics  
  - Corporate Finance, Goldman Sachs

Board of Directors

- **Florian Schönharting**  
  NB Capital

- **J. Kevin Buchi**  
  Tetralogic, previously Teva, Cephalon

- **Torsten Goesch, MD, PhD**  
  Rosetta Capital

- **Jan G. J. van de Winkel, PhD**  
  Genmab

Scientific Advisors

- **Fred Lublin, MD**  
  Mount Sinai Hospital

- **Giancarlo Comi, MD**  
  Hospital San Raffaela, Milan

- **Kristian Reich, MD**  
  Dermatologikum Hamburg

- **Jerry Wolinsky, MD**  
  University of Texas, Medical School

- **Per Soelberg Sørensen, MD**  
  Rigshospitalet, Copenhagen University Hospital

- **Ulrich Mrowietz, MD**  
  Psoriasis-Center Kiel

Select Investors

- **Nordic Biotech**

- **BioScience Managers Limited**

- **The Baupost Group**

- **BVF Partners LP**
**IP Key Upcoming Events**

- **June 24/25\(^{th}\), 2015**  
  '430 Patent: EPO opposition oral hearing

- **July 10, 2015**  
  '871 Interference: File authorized motions and priority statements

- **September 11, 2015**  
  '871 Interference: File oppositions to motions

- **January 22, 2016**  
  '871 Interference: Default oral argument

- **February 16, 2016**  
  German Utility Model: Oral proceeding scheduled
Key Upcoming Events

- Interference proceeding progress at the USPTO
- US: Progress on 480 mg/day MS patent applications
- EU: Progress on 480 mg/day MS patent applications
- MS clinical development progress
- Psoriasis clinical development progress